Cargando…
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy
BACKGROUND: A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. METHODS: We conducted a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019089/ https://www.ncbi.nlm.nih.gov/pubmed/31095341 http://dx.doi.org/10.1093/jnci/djz075 |
_version_ | 1783497448207941632 |
---|---|
author | Kerns, Sarah L Fachal, Laura Dorling, Leila Barnett, Gillian C Baran, Andrea Peterson, Derick R Hollenberg, Michelle Hao, Ke Narzo, Antonio Di Ahsen, Mehmet Eren Pandey, Gaurav Bentzen, Søren M Janelsins, Michelle Elliott, Rebecca M Pharoah, Paul D P Burnet, Neil G Dearnaley, David P Gulliford, Sarah L Hall, Emma Sydes, Matthew R Aguado-Barrera, Miguel E Gómez-Caamaño, Antonio Carballo, Ana M Peleteiro, Paula Lobato-Busto, Ramón Stock, Richard Stone, Nelson N Ostrer, Harry Usmani, Nawaid Singhal, Sandeep Tsuji, Hiroshi Imai, Takashi Saito, Shiro Eeles, Rosalind DeRuyck, Kim Parliament, Matthew Dunning, Alison M Vega, Ana Rosenstein, Barry S West, Catharine M L |
author_facet | Kerns, Sarah L Fachal, Laura Dorling, Leila Barnett, Gillian C Baran, Andrea Peterson, Derick R Hollenberg, Michelle Hao, Ke Narzo, Antonio Di Ahsen, Mehmet Eren Pandey, Gaurav Bentzen, Søren M Janelsins, Michelle Elliott, Rebecca M Pharoah, Paul D P Burnet, Neil G Dearnaley, David P Gulliford, Sarah L Hall, Emma Sydes, Matthew R Aguado-Barrera, Miguel E Gómez-Caamaño, Antonio Carballo, Ana M Peleteiro, Paula Lobato-Busto, Ramón Stock, Richard Stone, Nelson N Ostrer, Harry Usmani, Nawaid Singhal, Sandeep Tsuji, Hiroshi Imai, Takashi Saito, Shiro Eeles, Rosalind DeRuyck, Kim Parliament, Matthew Dunning, Alison M Vega, Ana Rosenstein, Barry S West, Catharine M L |
author_sort | Kerns, Sarah L |
collection | PubMed |
description | BACKGROUND: A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. METHODS: We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ancestry who underwent radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. We used grouped relative risk models to test associations with approximately 6 million genotyped or imputed variants (time to first grade 2 or higher toxicity event). Variants with two-sided P(meta) less than 5 × 10(−8) were considered statistically significant. Bayesian false discovery probability provided an additional measure of confidence. Statistically significant variants were evaluated in three Japanese cohorts (n = 962). All statistical tests were two-sided. RESULTS: Meta-analysis of the European ancestry cohorts identified three genomic signals: single nucleotide polymorphism rs17055178 with rectal bleeding (P(meta) = 6.2 × 10(−10)), rs10969913 with decreased urinary stream (P(meta) = 2.9 × 10(−10)), and rs11122573 with hematuria (P(meta) = 1.8 × 10(−8)). Fine-scale mapping of these three regions was used to identify another independent signal (rs147121532) associated with hematuria (P(conditional) = 4.7 × 10(−6)). Credible causal variants at these four signals lie in gene-regulatory regions, some modulating expression of nearby genes. Previously identified variants showed consistent associations (rs17599026 with increased urinary frequency, rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated Japanese cohorts. CONCLUSIONS: This study increases the understanding of the architecture of common genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, and develops risk models for testing in clinical studies. Further multinational radiogenomics studies in larger cohorts are worthwhile. |
format | Online Article Text |
id | pubmed-7019089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70190892020-02-20 Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy Kerns, Sarah L Fachal, Laura Dorling, Leila Barnett, Gillian C Baran, Andrea Peterson, Derick R Hollenberg, Michelle Hao, Ke Narzo, Antonio Di Ahsen, Mehmet Eren Pandey, Gaurav Bentzen, Søren M Janelsins, Michelle Elliott, Rebecca M Pharoah, Paul D P Burnet, Neil G Dearnaley, David P Gulliford, Sarah L Hall, Emma Sydes, Matthew R Aguado-Barrera, Miguel E Gómez-Caamaño, Antonio Carballo, Ana M Peleteiro, Paula Lobato-Busto, Ramón Stock, Richard Stone, Nelson N Ostrer, Harry Usmani, Nawaid Singhal, Sandeep Tsuji, Hiroshi Imai, Takashi Saito, Shiro Eeles, Rosalind DeRuyck, Kim Parliament, Matthew Dunning, Alison M Vega, Ana Rosenstein, Barry S West, Catharine M L J Natl Cancer Inst Articles BACKGROUND: A total of 10%–20% of patients develop long-term toxicity following radiotherapy for prostate cancer. Identification of common genetic variants associated with susceptibility to radiotoxicity might improve risk prediction and inform functional mechanistic studies. METHODS: We conducted an individual patient data meta-analysis of six genome-wide association studies (n = 3871) in men of European ancestry who underwent radiotherapy for prostate cancer. Radiotoxicities (increased urinary frequency, decreased urinary stream, hematuria, rectal bleeding) were graded prospectively. We used grouped relative risk models to test associations with approximately 6 million genotyped or imputed variants (time to first grade 2 or higher toxicity event). Variants with two-sided P(meta) less than 5 × 10(−8) were considered statistically significant. Bayesian false discovery probability provided an additional measure of confidence. Statistically significant variants were evaluated in three Japanese cohorts (n = 962). All statistical tests were two-sided. RESULTS: Meta-analysis of the European ancestry cohorts identified three genomic signals: single nucleotide polymorphism rs17055178 with rectal bleeding (P(meta) = 6.2 × 10(−10)), rs10969913 with decreased urinary stream (P(meta) = 2.9 × 10(−10)), and rs11122573 with hematuria (P(meta) = 1.8 × 10(−8)). Fine-scale mapping of these three regions was used to identify another independent signal (rs147121532) associated with hematuria (P(conditional) = 4.7 × 10(−6)). Credible causal variants at these four signals lie in gene-regulatory regions, some modulating expression of nearby genes. Previously identified variants showed consistent associations (rs17599026 with increased urinary frequency, rs7720298 with decreased urinary stream, rs1801516 with overall toxicity) in new cohorts. rs10969913 and rs17599026 had similar effects in the photon-treated Japanese cohorts. CONCLUSIONS: This study increases the understanding of the architecture of common genetic variants affecting radiotoxicity, points to novel radio-pathogenic mechanisms, and develops risk models for testing in clinical studies. Further multinational radiogenomics studies in larger cohorts are worthwhile. Oxford University Press 2019-05-16 /pmc/articles/PMC7019089/ /pubmed/31095341 http://dx.doi.org/10.1093/jnci/djz075 Text en © The Author(s) 2019. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Kerns, Sarah L Fachal, Laura Dorling, Leila Barnett, Gillian C Baran, Andrea Peterson, Derick R Hollenberg, Michelle Hao, Ke Narzo, Antonio Di Ahsen, Mehmet Eren Pandey, Gaurav Bentzen, Søren M Janelsins, Michelle Elliott, Rebecca M Pharoah, Paul D P Burnet, Neil G Dearnaley, David P Gulliford, Sarah L Hall, Emma Sydes, Matthew R Aguado-Barrera, Miguel E Gómez-Caamaño, Antonio Carballo, Ana M Peleteiro, Paula Lobato-Busto, Ramón Stock, Richard Stone, Nelson N Ostrer, Harry Usmani, Nawaid Singhal, Sandeep Tsuji, Hiroshi Imai, Takashi Saito, Shiro Eeles, Rosalind DeRuyck, Kim Parliament, Matthew Dunning, Alison M Vega, Ana Rosenstein, Barry S West, Catharine M L Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title_full | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title_fullStr | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title_full_unstemmed | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title_short | Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy |
title_sort | radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019089/ https://www.ncbi.nlm.nih.gov/pubmed/31095341 http://dx.doi.org/10.1093/jnci/djz075 |
work_keys_str_mv | AT kernssarahl radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT fachallaura radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT dorlingleila radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT barnettgillianc radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT baranandrea radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT petersonderickr radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT hollenbergmichelle radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT haoke radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT narzoantoniodi radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT ahsenmehmeteren radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT pandeygaurav radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT bentzensørenm radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT janelsinsmichelle radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT elliottrebeccam radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT pharoahpauldp radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT burnetneilg radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT dearnaleydavidp radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT gullifordsarahl radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT hallemma radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT sydesmatthewr radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT aguadobarreramiguele radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT gomezcaamanoantonio radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT carballoanam radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT peleteiropaula radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT lobatobustoramon radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT stockrichard radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT stonenelsonn radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT ostrerharry radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT usmaninawaid radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT singhalsandeep radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT tsujihiroshi radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT imaitakashi radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT saitoshiro radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT eelesrosalind radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT deruyckkim radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT parliamentmatthew radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT dunningalisonm radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT vegaana radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT rosensteinbarrys radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy AT westcatharineml radiogenomicsconsortiumgenomewideassociationstudymetaanalysisoflatetoxicityafterprostatecancerradiotherapy |